• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
73,918.76 394.50
( 0.54%)
Global Indices
Nasdaq
50,812.84 -74.94
(-0.15%)
Dow Jones
7,426.81 22.07
(0.30%)
Hang Seng
65,160.26 1,135.66
(1.77%)
Nikkei 225
10,368.25 0.20
(0.00%)
Forex
USD-INR
95.22 -0.51
(-0.53%)
EUR-INR
109.67 -1.54
(-1.39%)
GBP-INR
126.98 -1.60
(-1.25%)
JPY-INR
0.59 0.00
(-0.77%)

EQUITY - MARKET SCREENER

Remus Pharmaceuticals Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
78788
INE0O5T01011
276.4035981
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
REMUS
33.8
835.31
EPS(TTM)
Face Value()
Div & Yield %
20.97
10
0.07
 

NTPC Q4 PAT jumps 34% YoY to Rs 10,615 cr
May 23,2026
The revenue from power generation activity stood at Rs 48,548.49 crore in Q4 FY26, down 1.63% YoY. During the period under review, the company recorded Rs 4,704.92 crore as other income, up 6.18% YoY.

Profit before tax and regulatory deferral account balances surged 211.16% YoY to Rs 17,428.49 crore in Q4 FY26, driven by regulatory deferral account movements, tariff true-up adjustments, and accounting-related income recognition under CERC regulations.

Meanwhile, the board of directors has recommended a final dividend of 35% (Rs 3.50 per equity share of face value Rs 10 each) for FY26, subject to shareholder approval at the ensuing annual general meeting.

NTPC, along with its subsidiaries/associates & JVs, is primarily involved in the generation and sale of bulk power to state power utilities. Other business of the group includes providing consultancy, project management & supervision, energy trading, oil & gas exploration, and coal mining.

Shares of NTPC shed 0.13% to settle at Rs 388.45 on 22 May 2026.